Sep 27th 2012 - Edison Investment Research today published a report on Imperial Innovations (IVO.L, LSE:IVO, LON:IVO) entitled "PsiOxus Takes A Key Step Forward". In summary, the report says:
Imperial Innovations’ fourth-largest portfolio company, PsiOxus Therapeutics, has initiated the first stage of a128-patient Phase I/II study of its lead cancer immunotherapeutic, ColoAD1, in metastatic colorectal cancer. The trial start marks an important value-creating step for a company in which Imperial Innovations has a c 44% shareholding. It also brings a new clinical stage programme into the burgeoning oncolytic virus space.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »